Illumina has partnered with Vitrolife to sell our preimplantation genetic screening and karyomapping products in Europe, the Middle East, Africa, and the Americas. Vitrolife began taking customer orders in December of 2018 and transitioning all sales and support in early 2019. Both Illumina and Vitrolife are committed to ensuring a seamless transition.
VeriSeq PGS Kit
A next-generation sequencing solution that provides accurate chromosome screening for identification of in vitro embryos most likely to be euploid. Read More...
VeriSeq Preimplantation Genetic Screening (PGS) with BlueFuse
The VeriSeq PGS Kit takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for identification of in vitro embryos most likely to be euploid. Preimplantation genetic screening (PGS) results generated using the VeriSeq PGS Kit are comparable to those achieved with the widely used array-based 24sure technology. In addition, NGS offers the opportunity for improved assay workflow, higher throughput, and enhanced performance.1
Industry-leading data quality: More than 90% of the world’s sequencing data is generated by Illumina sequencing by synthesis (SBS) chemistry*
Fast, streamlined workflow: Sample to answer in approximately 12 hours
High-throughput analysis: Screen up to 24 samples per run
NGS offers a highly sensitive method for screening in vitro embryos, requiring as little as 1 ng of DNA from a SurePlex DNA amplification reaction. DNA can be obtained from a blastomere biopsy, from a day 3 embryo, or from a trophectodermal (TE) biopsy from a blastocyst.
Fiorentino F, Bono S, Biricik A, et al. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Hum Reprod. 2014;29(12):2802–2813.
Yang Z, Liu J, Collins GS, Salem SA, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis patients: results from a randomised pilot study. Mol Cytogenet. 2012;5: 24.